Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Yin

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Bioinformatics (Oxford, England)|November 13, 2014
MeRP: a high-throughput pipeline for Mendelian randomization analysisPeter Yin, Benjamin F Voight
Asian Journal of Neurosurgery|February 17, 2015
Recurrent artery of Heubner aneurysmYagnesh Vellore, Anoop Madan, Peter Yin Kai Hwang
Clinical Obesity|December 2, 2024
The real-world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart reviewSean Wharton, Elham Kamran, Lehana Thabane, et al.
Diabetes, Obesity & Metabolism|February 10, 2025
Characterization of the effect of naltrexone/bupropion on body compositionVanessa Tardio, Peter Yin, Fernando Camacho, et al.
Science (New York, N.Y.)|March 30, 2013
Amplifying genetic logic gatesJerome Bonnet, Peter Yin, Monica E Ortiz, et al.
Human Molecular Genetics|December 28, 2016
Serum calcium and risk of migraine: a Mendelian randomization studyPeter Yin, Verneri Anttila, Katherine M Siewert, et al.
International Journal of Obesity (2005)|June 4, 2021
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trialSean Wharton, Peter Yin, Melonie Burrows, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Bioinformatics (Oxford, England)|November 13, 2014
MeRP: a high-throughput pipeline for Mendelian randomization analysisPeter Yin, Benjamin F Voight
Asian Journal of Neurosurgery|February 17, 2015
Recurrent artery of Heubner aneurysmYagnesh Vellore, Anoop Madan, Peter Yin Kai Hwang
Clinical Obesity|December 2, 2024
The real-world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart reviewSean Wharton, Elham Kamran, Lehana Thabane, et al.
Diabetes, Obesity & Metabolism|February 10, 2025
Characterization of the effect of naltrexone/bupropion on body compositionVanessa Tardio, Peter Yin, Fernando Camacho, et al.
Science (New York, N.Y.)|March 30, 2013
Amplifying genetic logic gatesJerome Bonnet, Peter Yin, Monica E Ortiz, et al.
Human Molecular Genetics|December 28, 2016
Serum calcium and risk of migraine: a Mendelian randomization studyPeter Yin, Verneri Anttila, Katherine M Siewert, et al.
International Journal of Obesity (2005)|June 4, 2021
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trialSean Wharton, Peter Yin, Melonie Burrows, et al.
Pageof 1